PD-1 & PD-L1 Inhibitors
PD-1 & PD-L1 interaction between T-cells and tumour cells.
What are PD-1 and PD-L1?
PD-1, also known as programmed cell death 1, is a receptor expressed on the surface of T cells and plays a pivotal role in immune homeostasis, by keeping overstimulated responses at bay while safeguarding tissues from any unintended destruction. In essence, Programmed Cell Death Protein 1 (PD-1) keeps the body's immunity balanced. The ligands for PD-1 are programmed death-ligand 1 (PD-L1) and PD-L2, which are expressed on various cells including cancer cells, antigen-presenting cells, and non-immune cells.
PD-1 and its ligands are powerful players in suppressing immune responses to cancer, chronic infections, and autoimmune diseases. Cancer cells can take advantage of this by upregulating PD-L1; the interaction between PD-L1 and PD-1 on T cells blocks their activation process - granting tumors the opportunity to grow immune system activation.
Programmed death-1 (PD-1) ligand 1 (PD-L1), also known as CD274 and B7-H1, is a transmembrane protein commonly expressed on the surface of antigen presenting cells and tumor cells. PD-L1 binds to the PD-1 checkpoint receptor which is commonly found on lymphocytes such as T-cells. The PD-1/ PD-L1 pathway is an immune checkpoint pathway which downregulates T-cell activation and prevents T-cell immunity.
PD-1 also binds PD-L2, commonly known as CD273 and B7-DC. PD-L2 is highly expressed in many epithelial cancers and B-cell lymphomas. PD-L1 is often found on cells from solid tumors and in particular, PD-L1 has been shown to have high expression in ovarian cancer, melanoma and lung cancer. When PD-L2 binds to PD-1, the immune response is downregulated through the upregulation of PD-L1.
In particular, the interaction between PD-1 and PD-L1 leads to the phosphorylation of immune receptor tyrosine–based inhibitory motif (ITIM) and immune receptor tyrosine–based switch motif (ITSM) structure domain's of PD-1. Src homology 2 domain protein tyrosine phosphatase-2 (SHP-2) is then attracted. This leads to the downstream phosphorylation of spleen tyrosine kinase (Syk) and phospholipid inositol-3-kinase (PI3K), which in turn inhibits lymphocyte proliferation and cytokine secretion and much more. This interaction with PD-L1 also plays a role in the development of T regs which contribute to immunosuppression and limit anti-tumor immunity.
The association between the PD-1/PD-L1 pathway and cancer
Tumours often co-opt immune checkpoint protein pathways such as the PD-1/PDL-1 pathway as an immune resistance opportunity. This is why a lot of cancerous cells have high quantities of PD-L1 in order to avoid attack from the immune system. There have been major advancements in cancer therapy through the production of monoclonal antibodies specific for targeting PD-1 and PD-L1.
PD-1 and PD-L1 blocking was first published in 2001 for the treatment of cancer. In 2006, the first clinical trial was launched which evaluated the clinical efficacy of nivolumab. Other PD-1 inhibitors include pembrolizumab and cemiplimab. PD-L1 inhibitors include atezolizumab, durvalumab and avelumab. Studies have shown that PD-1 and PD-L1 inhibitors increase the number of T cells and activate them to fight tumor cells. In addition, these drugs also break down inhibitory pathways on T cells preventing them from being suppressed by the tumor microenvironment. These effects lead to an increased response rate and overall survival in cancer patients.
PD-1 and PD-L1 inhibitors are approved for the treatment of a variety of cancers including non–small cell lung cancer, melanoma, head and neck cancer, renal cell carcinoma and bladder cancer. They have been shown to be effective in both monotherapy or combination therapy with other drugs like chemotherapy or radiation therapy. Clinical trials are underway to evaluate the efficacy of these drugs in other types of cancer.
PD-L1 Inhibitors
Atezolizumab is a humanized IgG1 monoclonal anti-PD-L1 antibody that was approved by the U.S Food Drug Administration (FDA) in 2016. Atezolizumab has been approved for the treatment of extensive-stage Small Cell Lung Cancer (SCLC), Metastatic Non-small-cell Lung Cancer (NSCLC), Metastatic Triple-negative Breast Cancer, Unresectable or Metastatic Melanoma, Unresectable or Metastatic Hepatocellular Carcinoma and Locally Advanced or Metastatic Urothelial Carcinoma.
Avelumab, sold under the brand name Bavencio®, was approved by the FDA to be used as a maintenance therapy in people with locally advanced or metastatic urothelial carcinoma who have failed first-line platinum-containing treatment.
Durvalumab is a monoclonal antibody that targets PD-L1. It is used to treat urothelial cancers that are locally advanced or metastatic and have progressed during or following platinum-containing chemotherapy. Durvalumab can also be given to unresectable stage III NSCLC patients who have not had any progress after concurrent platinum-based chemotherapy.
PD-1 Inhibitors
Pembrolizumab, more commonly known as Keytruda®, is a humanized immunoglobulin G1 kappa monoclonal antibody that works by increasing the ability of the immune system to fight against cancer. Specifically, pembrolizumab blocks the interaction between the PD-1 receptor on T-cells and its ligands. Pembrolizumab can be used against many cancers such as breast cancer, colorectal cancer, renal cell carcinoma, skin cancer and much more.
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to PD-1. This checkpoint inhibitor is used to treat patients suffering from NSCLC, melanoma, renal cell cancer, Hodgkin's lymphoma, urothelial carcinoma, lung cancer and much more.
Cemiplimab is an antibody against PD-1. This checkpoint inhibitor is used to treat metastatic cutaneous squamous cell carcinoma, NSCLC, advanced and metastatic basal cell carcinoma.
Dostarlimab was was approved by the FDA in 2021 for the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.
PD-1 inhibitors:
- Pembrolizumab (Keytruda®)
- Nivolumab (Opdivo®)
- Cemiplimab (Libtayo®)
PD-L1 inhibitors:
Side Effects of PD-1 & PD-L1 Inhibitors
The side effects associated with PD-1 and PD-L1 inhibitors include fatigue, itching, rash, diarrhea and anemia. In some cases they can also cause immune related adverse events such as pneumonitis or colitis. The risk of these side effects increases with higher doses or prolonged use. Therefore, it is important to monitor patients closely for these reactions and adjust the treatment accordingly.
PD-1 Antibody Clones for Research
Choosing the right one for your research
A Comparison of PD-1 Clones
Assay Genie offers two anti-mouse PD-1 clones including RMP1-14 and 29F.1A12. Both of these clones bind to and thus block PD-1 signalling. Of the clones, RMP1-14 has the greatest number of publications for in vivo blocking and are used to study the in vivo blocking of PD-1 and PD-L signalling. The 29.F.1A12 clone can also be used for PD-1 blocking studies however it may also be used for in vitro western blotting, neutralization, immunohistochemistry, flow cytometry and immunofluorescence.
Comparison of PD-1 Antibody Clones
Clone | RMP1-14 | 29F.1A12 |
Product Code Low Endotoxin Ultra Low Endotoxin |
||
Isotype |
Rat IgG2a κ |
Rat IgG2a κ |
Applications |
B, FA, WB |
B, FC, WB, IHC, FF CyTOF®, PhenoCycler® |
Immunogen |
Mouse PD-1 transfected BHK cells |
PD-1 cDNA followed by PD-1-Ig fusion protein |
Purity Low Endotoxin Ultra Low Endotoxin |
>95% >98% |
>95% >98% |
Stabilizers or Preservatives |
Free |
Free |
Recommended Isotype Control Low Endotoxin Ultra Low Endotoxin |
Related tools for research
Related Immunology Content
- Adhesion Molecules in Atherosclerosis - ICAM1
- Adaptive Immunity
- B Cells
- Brown Fat Macrophages
- Carbon Dioxide Signalling in Immune Cells
- Cortisol and the immune response
- Chemokines & Chemokine Receptors
- Dendritic Cells
- Immunometabolism Assays
- Inflammation & Aging Review
- Inflammation & Obesity Review
- Glycolysis Assay Kits
- Heterogeneity of Type 1 diabetes in children
- Macrophages
- Neutophils
- Natural Killer (NK) Cells
- Natural Killer Cells & Metabolism Review
- NLRP3 Inflammasome
- Mononuclear Phagocytes Review
- Multiple Sclerosis and Stem Cells
- Platelet reactivity & Diet Review
- SOCS proteins review
- TCA assay Kits
- T Cell assay types
- T Cells & Acute Leukemia Review
- T Cells & Hepatitis Review
- T Cell Metabolism
- T Cell responses in Diabetes
- TNF alpha & Inflammation
- TLR mediated Inflammation Review
- TLR Signalling & Neurodegeneration Review
- Trauma Immunology
- Wnt Signalling Pathway in Immunity
- What is Sepsis?
Recent Posts
-
Targeting IL-10R: Enhancing Immune Activation in Cancer
Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL …28th Nov 2024 -
Enoblituzumab Biosimilar : A New Era in B7-H3-Targeted Cancer Immunotherapy
Enoblituzumab is a monoclonal antibody targeting B7-H3 (CD276), a member of the B7 fam …28th Nov 2024 -
Siltuximab Biosimilar : Advancing IL-6 Targeted Therapies
Siltuximab, a monoclonal antibody targeting interleukin-6 (IL-6), is a key therapy for …28th Nov 2024